$0.45
+0.07 (+16.93%)
Open$0.40
Previous Close$0.38
Day High$0.47
Day Low$0.39
52W High$2.88
52W Low$0.34
Volume—
Avg Volume186.3K
Market Cap11.02M
P/E Ratio—
EPS$-1.92
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+621.6% upside
Current
$0.45
$0.45
Target
$3.24
$3.24
$1.82
$3.24 avg
$4.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 31.5K | 182.5K | 15.18M |
| Net Income | -86,030,440 | -448,854,469 | 1.21M |
| Profit Margin | -279,263.6% | -265,300.5% | 8.0% |
| EBITDA | -92,481,306 | -509,317,337 | 1.98M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | -82.8% | -82.8% | +1.7% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |